Compare · DXCM vs SSII
DXCM vs SSII
Side-by-side comparison of DexCom Inc. (DXCM) and SS Innovations International Inc. (SSII): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SSII operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $26.59B, about 39.1x SSII ($680.4M).
- Over the past year, DXCM is down 21.3% and SSII is down 39.3% - DXCM leads by 18.0 points.
- DXCM has been more active in the news (18 items in the past 4 weeks vs 9 for SSII).
- DXCM has more recent analyst coverage (25 ratings vs 0 for SSII).
- Company
- DexCom Inc.
- SS Innovations International Inc.
- Price
- $68.89-0.24%
- $3.44-2.27%
- Market cap
- $26.59B
- $680.4M
- 1M return
- -4.14%
- -11.45%
- 1Y return
- -21.33%
- -39.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 18
- 9
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
Latest SSII
- SS Innovations International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by SS Innovations International Inc.
- SS Innovations International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form S-8 filed by SS Innovations International Inc.
- CEO - Asia Pacific Vishwajyoti Pascual Srivastava received a gift of 1,000,000 shares (SEC Form 4)
- Chairman and CEO Sudhir Srivastava gifted 1,000,000 shares (SEC Form 4)
- SS Innovations International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SS Innovations Announces Completion of World's Longest-Distance Robotic Telesurgery
- COO - Americas Cohen Barry F gifted 25,000 shares, decreasing direct ownership by 0.32% to 7,755,088 units (SEC Form 4)
- SS Innovations International Inc. filed SEC Form 8-K: Leadership Update